Product category:
Genomics
News Release from: Cambridge BioScience | Subject: Transit-Prostate
Edited by the Laboratorytalk Editorial
Team on 21 August 2003
Optimising transfection of prostate cell
lines
New transfection kit for use in cancer research shows superior transfection efficiency in prostate cells without compromising cellular health
Gene transfer specialist Mirus has developed the new Transit-Prostate transfection kit for use in cancer research The kit shows superior transfection efficiency in prostate cells without compromising cellular health
This article was originally published on Laboratorytalk on 4 Jul 2005 at 8.00am (UK)
Related stories
Monoclonal antibody to mouse IPC
Inhibitory antibody reacts with a cell-surface molecule selectively expressed on mouse inteferon producing cells
As with the entire Transit range, it is efficient, simple to use, has low toxicity and high reproducibility.
High specificity makes the Transit-Prostate transfection kit a desirable alternative to broad spectrum transfection reagents for use with the prevalent cell lines in prostate cancer research.
These are often difficult to transfect using traditional methods.
The new kit is designed to achieve greater than 50% transfection efficiencies using GFP as a reporter in the common prostate cancer cell lines: DU-145, LNCaP-FGC, and PC-3.
Reagents are all supplied ready for use and can be used with serum-containing media.
The recommended method does not require media to be replaced, increasing ease and efficiency.
• Cambridge BioScience: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
